A discussion of the link between hearing loss and cardiovascular disease with Paul Mick, MD, and Anil K Lalwani, MD.

Wearable equipment-based telemedical management via multiparameter monitoring can help improve management in older patients with coronary heart disease.

Many patients with advanced cancer receive potentially aggressive care in the last month of life at the expense of supportive care.

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

A scientific statement regarding clinical considerations for athletes with cardiovascular abnormalities has been published by the AHA and ACC.

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The use of short-term hormone therapy for menopause is not associated with long-term cognitive impact after 10 years.

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Electronic symptom monitoring with patient-reported outcomes (PRO) meaningfully improves clinical outcomes for cancer treatment.

A study has found that in patients with ischemic heart disease receiving ventricular tachycardia ablation there is higher risk of mortality.